KEYTRUDA® (Pembrolizumab)

The FDA on November 13, 2020 granted accelerated approval to KEYTRUDA® in combination with chemotherapy for the treatment of patients with locally recurrent unresectable or metastatic Triple-Negative Breast Cancer (TNBC) whose tumors express PD-L1 (CPS 10 or more), as determined by an FDA approved test. KEYTRUDA® is a product of Merck & Co.